AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35672688 — intervention group
Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A) - 18 half-hour in-office therapy sessions for 3 months
Number of subjects: 60
Study 35672688 — intervention group
Group type: COMPARATOR
Intervention: Conventional patching (group B) - 2 hours of patching per day at home for 3 months
Number of subjects: 60
Study 35672688 — intervention group
Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A)
Number of subjects: 60
Study 35672688 — intervention group
Group type: COMPARATOR
Intervention: Conventional patching (group B)
Number of subjects: 60
Study 35672688 — intervention group
Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A) and Conventional patching (group B)
Number of subjects: 60
Study 35672754 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment after Monteggia injury
Number of subjects: 35
Study 35672754 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A (ulnar fracture site < 7 cm)
Number of subjects: 35
Study 35672754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with accompanying injury of the coronoid process
Number of subjects: 35
Study 35672758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum bottle plus non-tunneled catheter drainage
Number of subjects: 52
Study 35672758 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52
Study 35672860 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation (within first 8 hours after vasopressor start)
Number of subjects: 735
Study 35672860 — intervention group
Group type: COMPARATOR
Intervention: Unexposed (non-early intubated subjects)
Number of subjects: 735
Study 35672923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (dosage and duration not available)
Number of subjects: 0
Study 35673512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glucose (evening-time)
Number of subjects: 32
Study 35673512 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) profiling
Number of subjects: 32
Study 35674086 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP4-IgG
Number of subjects: 0
Study 35674086 — intervention group
Group type: EXPERIMENTAL
Intervention: MOG-IgG
Number of subjects: 0
Study 35674086 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP, GRP78 and other novel targets
Number of subjects: 0
Study 35674343 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of childhood cancer
Number of subjects: 571
Study 35674343 — intervention group
Group type: COMPARATOR
Intervention: Matched sample from the National Health and Nutrition Examination Survey
Number of subjects: 571
Study 35674351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound for quantification of hepatic steatosis
Number of subjects: 0
Study 35674351 — intervention group
Group type: COMPARATOR
Intervention: MRI Proton Density Fat Fraction as reference standard
Number of subjects: 0
Study 35674389 — intervention group
Group type: EXPERIMENTAL
Intervention: CSCs frequency in locally advanced-stage patients
Number of subjects: 22
Study 35674389 — intervention group
Group type: EXPERIMENTAL
Intervention: RG expression in CSCs
Number of subjects: 22
Study 35674389 — intervention group
Group type: COMPARATOR
Intervention: RG expression in cancer cells
Number of subjects: 22
Study 35674389 — intervention group
Group type: COMPARATOR
Intervention: CSCs frequency in early-stage patients
Number of subjects: 22
Study 35674480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (dosage not specified, administered daily)
Number of subjects: 21
Study 35674661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus Lenalidomide
Number of subjects: 3454
Study 35674698 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 113
Study 35674880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (5-mg subcutaneous dose)
Number of subjects: 32
Study 35675370 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (mRNA vaccine)
Number of subjects: 315
Study 35675590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT)
Number of subjects: 30
Study 35675590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib with chemotherapy followed by alloHSCT
Number of subjects: 30
Study 35675593 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh repair (TVM)
Number of subjects: 710
Study 35675593 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair (NTR)
Number of subjects: 710
Study 35675655 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35675673 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35675911 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35676012 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 8
Study 35676012 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stents (DP-DES)
Number of subjects: 8
Study 35676013 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of expressed human milk at 2 weeks postpartum
Number of subjects: 315
Study 35676017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model derived from high dimensional data set including epidemiological, psychometric, quantitative sensory, brain imaging and biological information
Number of subjects: 0
Study 35676062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and nivolumab combination therapy
Number of subjects: 41
Study 35676068 — intervention group
Group type: EXPERIMENTAL
Intervention: CURB (combined use of radiofrequency ablation and balloon dilation)
Number of subjects: 19
Study 35676666 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Osteoarthritis Self-Management Programme (SOASP)
Number of subjects: 143
Study 35676705 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearSight system (CSCO)
Number of subjects: 125
Study 35676705 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter bolus thermodilution (TDCO)
Number of subjects: 125
Study 35676708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 387
Study 35676708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 387
Study 35676898 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTER tool
Number of subjects: 150
Study 35676898 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 35677040 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment during pregnancy
Number of subjects: 124
Study 35677040 — intervention group
Group type: COMPARATOR
Intervention: No antiviral treatment during pregnancy
Number of subjects: 124
Study 35677040 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-pregnant women
Number of subjects: 124
Study 35677073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 60
Study 35677318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 0
Study 35677551 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate High-Fat (VLCHF) diet
Number of subjects: 91
Study 35677551 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 91
Study 35677553 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital healthcare intervention (DHI) designed to prevent post-transplant weight gain, accessed for 12 weeks.
Number of subjects: 20
Study 35677553 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group received standard dietary and physical activity advice.
Number of subjects: 20
Study 35677674 — intervention group
Group type: EXPERIMENTAL
Intervention: PrAISED - promoting activity, independence, and stability in early dementia
Number of subjects: 0
Study 35677674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35677684 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography guidance
Number of subjects: 60
Study 35677684 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 60
Study 35677691 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-derived high-risk plaque characteristics (HRPCs)
Number of subjects: 158
Study 35677691 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-derived hemodynamic parameters
Number of subjects: 158
Study 35677691 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk factors
Number of subjects: 158
Study 35677980 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with CVT
Number of subjects: 2313
Study 35677980 — intervention group
Group type: EXPERIMENTAL
Intervention: First 5 months of 2021
Number of subjects: 2313
Study 35677980 — intervention group
Group type: COMPARATOR
Intervention: First 5 months of 2020
Number of subjects: 2313
Study 35677980 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced immune thrombotic thrombocytopenia (VITT) cases in the first 5 months of 2021
Number of subjects: 2313
Study 35677980 — intervention group
Group type: COMPARATOR
Intervention: Overall CVT hospitalization volume during the 1st year of the COVID-19 pandemic
Number of subjects: 2313
Study 35678128 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized, pharmacy-led penicillin allergy evaluation and single-dose oral challenge
Number of subjects: 23
Study 35678128 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys distributed to health care personnel
Number of subjects: 23
Study 35678188 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of perceived social support
Number of subjects: 153
Study 35678188 — intervention group
Group type: COMPARATOR
Intervention: Lower level of perceived social support
Number of subjects: 153
Study 35678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 70-mg with nivolumab and ipilimumab
Number of subjects: 10
Study 35678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 50-mg with nivolumab and ipilimumab
Number of subjects: 10
Study 35678233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat (both doses)
Number of subjects: 10
Study 35678263 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour fasting
Number of subjects: 47
Study 35678724 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Number of subjects: 80
Study 35678881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (yes)
Number of subjects: 674
Study 35678881 — intervention group
Group type: COMPARATOR
Intervention: No diabetes (no)
Number of subjects: 674
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Course of diabetes >60 months
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive albuminuria
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerosis
Number of subjects: 492
Study 35679002 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood deficiency syndrome
Number of subjects: 492
Study 35679119 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (NEWS, ABCNO, wish list score)
Number of subjects: 217
Study 35679119 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (ABCNO score)
Number of subjects: 217
Study 35679119 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (wish list scoring criteria)
Number of subjects: 217
Study 35679476 — intervention group
Group type: EXPERIMENTAL
Intervention: axi-cel (autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Number of subjects: 171
Study 35679476 — intervention group
Group type: COMPARATOR
Intervention: SCHOLAR-5 (external control)
Number of subjects: 171
Study 35679614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness assessment
Number of subjects: 45
Study 35679614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat oxidation measurement during exercise
Number of subjects: 45
Study 35679700 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics features model (R)
Number of subjects: 154
Study 35679700 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors model (C)
Number of subjects: 154
Study 35679700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameters model (R + C)
Number of subjects: 154
Study 35679700 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM(R + C)
Number of subjects: 154
Study 35679775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory polygraphy findings (min SaO₂, T90, CAI/h)
Number of subjects: 204
Study 35679775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 204
Study 35679775 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory event index (REI) at least 30/h
Number of subjects: 204
Study 35679775 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors (male gender, older age, diabetes, mRS, GCS, CAI/h)
Number of subjects: 204
Study 35679775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease (PAD) and NIHSS score
Number of subjects: 204
Study 35679785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavlovian fear learning task during functional magnetic resonance imaging
Number of subjects: 282
Study 35679962 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ERN and CRN amplitudes
Number of subjects: 100
Study 35679962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lab-based neural measures (ERN and CRN)
Number of subjects: 100
Study 35680043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles or until disease progression or unacceptable toxicity
Number of subjects: 351
Study 35680043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 351
Study 35680172 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 15725
Study 35680172 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 15725
Study 35680172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 15725
Study 35680182 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with previous preeclampsia
Number of subjects: 1417
Study 35680182 — intervention group
Group type: COMPARATOR
Intervention: Age- and parity-matched women from the general population
Number of subjects: 1417
Study 35680192 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR using SAPIEN 3 valve with commissural misalignment (CMA)
Number of subjects: 324
Study 35680213 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography-derived fractional flow reserve (FFR)
Number of subjects: 260
Study 35680213 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 260
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of <5 mg prednisone equivalent per day
Number of subjects: 1066
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of ≥5 mg/day
Number of subjects: 1066
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of exactly 5 mg/day
Number of subjects: 1066
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of >7.5 mg/day in rheumatoid arthritis (RA) patients
Number of subjects: 1066
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of ≤5 mg/day
Number of subjects: 1066
Study 35680387 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of >7.5 mg/day in RA patients with moderate to high disease activity
Number of subjects: 1066
Study 35681157 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCARE model
Number of subjects: 0
Study 35681157 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35681574 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy (Cohort A: dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; Cohort B: 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel)
Number of subjects: 0
Study 35681595 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR fluorescence ARM procedure
Number of subjects: 109
Study 35681678 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 18
Study 35681678 — intervention group
Group type: COMPARATOR
Intervention: Radical chemoradiotherapy (rCRT)
Number of subjects: 18
Study 35683398 — intervention group
Group type: EXPERIMENTAL
Intervention: Home microsampling for quantification of adalimumab (ADM) concentrations using volumetric absorptive microsampling (VAMS)
Number of subjects: 0
Study 35683398 — intervention group
Group type: COMPARATOR
Intervention: Lateral flow testing (LFT)
Number of subjects: 0
Study 35683398 — intervention group
Group type: COMPARATOR
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 0
Study 35683419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 393
Study 35683419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) with clinical score
Number of subjects: 393
Study 35683423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention by a geriatrician and a cardiologist
Number of subjects: 141
Study 35683423 — intervention group
Group type: COMPARATOR
Intervention: Cardiologist alone (Control)
Number of subjects: 141
Study 35683592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy (intracoronary cell-based therapy)
Number of subjects: 1715
Study 35683592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 1715
Study 35684099 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF) supplemented with 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) for 4 months.
Number of subjects: 32
Study 35684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean diet (70.8% in group 1, highest quality of life)
Number of subjects: 305
Study 35684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal levels of muscle strength
Number of subjects: 305
Study 35684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed and agility
Number of subjects: 305
Study 35684122 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility
Number of subjects: 305
Study 35685496 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 463
Study 35685496 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 463
Study 35685496 — intervention group
Group type: COMPARATOR
Intervention: APT
Number of subjects: 463
Study 35685504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation (OAC) therapy
Number of subjects: 7698
Study 35685504 — intervention group
Group type: COMPARATOR
Intervention: No Oral Anticoagulation (OAC) therapy
Number of subjects: 7698
Study 35685868 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA-LBW infants
Number of subjects: 8360
Study 35685890 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed infant formula (HF)
Number of subjects: 0
Study 35685890 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (RF)
Number of subjects: 0
Study 35686079 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID+ patients
Number of subjects: 29
Study 35686079 — intervention group
Group type: COMPARATOR
Intervention: COVID- controls
Number of subjects: 29
Study 35686190 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS stimulation while watching neutral videos
Number of subjects: 89
Study 35686190 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS stimulation while watching smoking-related videos
Number of subjects: 89
Study 35686190 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation while watching smoking-related videos
Number of subjects: 89
Study 35686441 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk intake
Number of subjects: 130
Study 35686441 — intervention group
Group type: EXPERIMENTAL
Intervention: High egg intake
Number of subjects: 130
Study 35686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry intake
Number of subjects: 130
Study 35686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models for predicting grade 1 to 3 CIAEs
Number of subjects: 130
Study 35686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models for predicting grade 2/3 CIAEs
Number of subjects: 130
Study 35686551 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 0
Study 35686551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35686702 — intervention group
Group type: EXPERIMENTAL
Intervention: alfapump® implantable device
Number of subjects: 106
Study 35687173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 917
Study 35687173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 917
Study 35687173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages)
Number of subjects: 917
Study 35687390 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home exercises with visual feedback using the Valedo Home exergame, 9 sessions of 20 minutes over 3 weeks (T2-T3)
Number of subjects: 32
Study 35687390 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home exercises with visual feedback using the Valedo Home exergame
Number of subjects: 32
Study 35687390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32